Molecular testing looks past what a cancer looks like under the microscope to the changes in its genes that make it grow. Two people with the same type of cancer can have very different tumors at the genetic level, and that can mean different best treatments. The test can be run on tissue already removed at biopsy or surgery, and increasingly on an ordinary blood draw, so for many people it decides which drug comes first rather than adding a new procedure.
What Molecular Testing Looks For
The test reads changes in individual genes, and in the RNA messages and proteins those genes make.1Exploration of Medicine. Molecular diagnostics in clinical oncology: an overview Your report may call each finding a biomarker, meaning a measurable change in the cancer that doctors can act on. Modern tests check hundreds of genes at once for small mutations, extra or missing gene copies, and genes fused together.2Journal of Bio-X Research. A narrative review of cancer molecular diagnostics: past, present, and future
Different kinds of change matter for different reasons. A gene fusion, where two genes break and join, drives some lung cancers, such as those with ALK or ROS1 fusions. A single-letter mutation, such as in EGFR, KRAS or BRAF, is another common finding in lung and colon cancers. Drugs exist that block the abnormal protein some of these changes produce.
Your cancer’s genes differ from your normal ones because cancer cells pick up DNA changes as they divide that normal cells don’t have. Some of these changes act like a stuck accelerator, telling the cell to keep growing.
Testing is routine for advanced lung, colon and breast cancers and melanoma, among several others. For some cancers it is offered mainly when standard treatments run out. Asking your oncologist whether it’s standard for your cancer type is a reasonable first question.
A report typically lists each gene tested, the specific change found, and whether doctors can act on it with a drug, so reading it means looking for the gene name and the change beside it. Many reports also list changes with no current drug or clear meaning, so a long list does not mean a long list of treatment options.
How a Tumor Sample Is Tested
Tumor tissue is soaked in formalin and set in a paraffin wax block so it can be stored and cut into slices. Formalin can damage DNA, though, breaking it into pieces and creating false-looking letter changes.3PubMed Central. Formalin-fixed paraffin-embedded sample conditions for deep next generation sequencing Fixation needs to happen right after removal and for the right length of time, since too long or too short both harm the DNA.3PubMed Central. Formalin-fixed paraffin-embedded sample conditions for deep next generation sequencing Stored blocks also keep degrading, and blocks kept 4 to 6 years can yield far less usable DNA.4PubMed. DNA degrades during storage in formalin-fixed and paraffin-embedded tissue blocks If an old sample is used, the lab may ask for a fresh biopsy or blood sample.
For a tissue test, you often do nothing new, because tissue from your diagnostic biopsy is reused. If too little tissue remains, a repeat biopsy or a blood test may be offered.
In the lab, a pathologist first marks the area of the slide with the most cancer cells, since normal cells mixed in dilute the signal. The lab cuts thin slices from the block and extracts DNA or RNA from the marked area. That material is prepared for sequencing, read by the machine, and compared against a reference to flag differences. A specialist then reviews the flagged changes and writes the report that goes to your oncologist.
Most labs read many genes at once. Next-generation sequencing (NGS) reads millions of short pieces of DNA at the same time, and your report may name it.2Journal of Bio-X Research. A narrative review of cancer molecular diagnostics: past, present, and future A focused panel of chosen genes reads each spot more times than sequencing all genes does, which finds important changes at lower cost with fewer unclear results.5PubMed Central. Development and validation of a targeted next generation DNA sequencing panel outperforming whole exome sequencing for the identification of clinically relevant genetic variants Some labs read RNA as well, which finds gene fusions more reliably from smaller samples.6Cytopathology. A More Accurate, Less Invasive Analysis for Lung Cancers: RNA Next-Generation Sequencing Reading DNA and RNA together can add cost and time, though the two catch what the other misses.7PubMed Central. An accurate DNA and RNA based targeted sequencing assay for clinical detection of gene fusions in solid tumors
Older single-target tests are still used. Some fusions are checked with a stain that colors the abnormal protein; for ROS1, the stain caught every true case in one comparison.8PubMed Central. Detection of ROS1 Gene Rearrangement in Lung Adenocarcinoma: Comparison of IHC, FISH and Real-Time RT-PCR A stain can also flag cases that turn out negative on other tests, so a positive is often confirmed by a second method.9PubMed Central. Comparison of IHC, FISH and RT-PCR Methods for Detection of ALK Rearrangements in 312 Non-Small Cell Lung Cancer Patients in Taiwan
Testing Tumor DNA in a Blood Sample
Tumors release bits of their DNA into the bloodstream.10PubMed. Circulating tumor DNA and liquid biopsy in oncology A liquid biopsy, a blood draw tested for this DNA, can detect and describe a cancer without cutting tissue.10PubMed. Circulating tumor DNA and liquid biopsy in oncology Because the tumor DNA is swamped by normal DNA, the test has to find very rare fragments.11PubMed Central. The Clinical Utility of Droplet Digital PCR for Profiling Circulating Tumor DNA in Breast Cancer Patients
One method splits a sample into about 20,000 tiny droplets so each rare fragment can be spotted alone.11PubMed Central. The Clinical Utility of Droplet Digital PCR for Profiling Circulating Tumor DNA in Breast Cancer Patients For EGFR changes in lung cancer, this approach can find mutated DNA making up as little as 0.04% of the total.12PubMed. Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer A negative blood test still doesn’t rule a change out if the tumor is shedding little DNA.
Doctors lean on blood when a biopsy would be risky, such as a tumor in a hard-to-reach spot or a patient too unwell for a procedure, or when not enough tissue is left. It can also give answers faster when treatment decisions can’t wait for tissue processing. And after a targeted drug stops working, a new blood draw can show whether the cancer picked up a new change that explains it.
The draw itself is a normal one from the arm, usually a few tubes, and no fasting is usually needed. The tubes go to a specialized lab, often out of state.
How Results Guide Treatment
Among people with advanced cancer who had run out of standard options, about 16 in 100 on a test-matched drug saw tumors shrink, versus about 5 in 100 on unmatched drugs.13American Health & Drug Benefits. IMPACT: Matching Treatment and Molecular Testing Extends Survival in Advanced Cancer Median survival in that group was 9.3 months with matched treatment versus 7.3 months without.13American Health & Drug Benefits. IMPACT: Matching Treatment and Molecular Testing Extends Survival in Advanced Cancer In early drug trials, matched treatment kept cancer in check about 6.5 months versus under 3 months unmatched.14PubMed Central. Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study The test improves the odds but usually doesn’t turn advanced cancer into a cure. These figures are averages across groups, and a shrinking tumor in about 16 of 100 people means most still did not respond, even with a match.
Some results point to immunotherapy. MSI-high (broken DNA spell-checking) and TMB-high (many mutations) predict response to immunotherapy drugs.15PubMed Central. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers They don’t always occur together, so a cancer can be MSI-high without being TMB-high.16PubMed Central. Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients Pembrolizumab is approved for MSI-high solid tumors of any type, and some people qualify only through that result.16PubMed Central. Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients
Many tumors have no change with an approved matching drug. In that case standard chemotherapy or immunotherapy remains the plan. An unmatched finding can still open the door to a clinical trial, and results can be revisited later as new drugs appear. When results come back, useful questions are whether there is an approved drug for this change in your cancer type, whether there are clinical trials for it, and whether it affects immunotherapy choices.
How Accurate the Results Are
In proficiency testing for BRAF, EGFR and KRAS, both FDA-approved kits and labs’ own tests were over 97% accurate.17PubMed Central. Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing Most labs using an approved kit adapt it, so a lab’s own test isn’t a sign of lower quality.17PubMed Central. Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing
Blood tests have a particular weak spot. As people age, some blood cells pick up mutations of their own. A liquid biopsy can then report a mutation that came from white blood cells, not the tumor, as in one reported esophageal cancer case.18PubMed Central. Liquid biopsy in esophageal cancer: a case report of false-positive circulating tumor DNA detection due to clonal hematopoiesis Low-level changes in blood DNA, under about 10% of fragments, are especially prone to such errors.19PubMed Central. Utility of plasma cell-free DNA for de novo detection and quantification of clonal hematopoiesis When a blood result doesn’t fit, doctors may test white blood cells or tissue to confirm.
Tissue and blood can also disagree without either being wrong. Tumors are not uniform, so different parts of the same cancer can carry different changes. A biopsy samples a single spot, while blood carries DNA shed from all tumor sites at once. A change found in one sample but not the other is therefore not automatically a mistake. Your doctor will weigh both, and may repeat a test if the choice of drug depends on it.
Some findings are labeled a variant of uncertain significance, a change whose effect isn’t yet known. Much sequencing data can’t yet be interpreted, and meanings can change over time.20PubMed. Ethical challenges of precision cancer medicine An uncertain result shouldn’t drive treatment on its own.
How Long Results Take and What They Cost
Ideally results are ready at the first oncology visit, but long lab turnaround often prevents it.21PubMed Central. Barriers and Unequal Access to Timely Molecular Testing Results: Addressing the Inequities in Cancer Care Delays across Canada When testing isn’t standard care for a tumor type, out-of-pocket cost is often several thousand dollars at minimum.21PubMed Central. Barriers and Unequal Access to Timely Molecular Testing Results: Addressing the Inequities in Cancer Care Delays across Canada
A few steps can head off delay and surprise bills. Ask your care team early whether testing has been ordered and whether the lab has received your sample, since delays often come from paperwork or shipping. Contact the lab or your insurer before testing to ask whether it is covered and what you might owe. Many testing companies run financial assistance programs, so ask before assuming you must pay in full.
Starting the wrong drug first can cost time, and some targeted drugs work best as the first treatment. Your doctor weighs how fast the cancer is moving, so ask whether it is safe to start treatment before results arrive for your cancer type.
Tumor Testing Versus Inherited Gene Testing
Germline testing looks at the genes you were born with, usually from blood or saliva, while tumor testing looks at changes in the cancer. Tumor testing can’t tell an inherited change from one that arose in the tumor.22PubMed Central. Genetic Testing Utilization: Discrepancies Between Somatic and Germline Results in Patients With Cancer Reviewed at the UW Health Precision Medicine Molecular Tumor Board Tumor panels also don’t analyze all the genes that inherited tests include.22PubMed Central. Genetic Testing Utilization: Discrepancies Between Somatic and Germline Results in Patients With Cancer Reviewed at the UW Health Precision Medicine Molecular Tumor Board
A tumor report can hint at inherited risk but not prove it. Some changes in genes such as BRCA1 and BRCA2 appear in nearly all of the tumor’s DNA, which can raise suspicion. Confirming it takes a separate test on blood or saliva.
It’s worth asking about inherited testing if the tumor report flags a possible inherited change, or if close relatives had cancer, especially young. The results matter for relatives’ screening, not just your treatment.
Blood Tests to Watch for Recurrence
After surgery, leftover tumor DNA in the blood can signal cancer cells that remain.23PubMed. Minimal residual disease as a target for liquid biopsy in patients with solid tumours Repeated testing over time finds a median of about 89% of recurrences.24PubMed Central. Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease It spotted returning cancer a median of 5.8 months before standard scans.24PubMed Central. Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease In one early breast cancer group, a negative result came with about a 2% five-year recurrence risk versus about 42% when positive.25PubMed Central. Dual ctDNA and CTCs analysis for minimal residual disease detection and relapse monitoring in early-stage breast cancer
These tests are newer and not standard for every cancer. If you’re finishing treatment, ask whether they are covered and whether results would change your care, since an early warning is most useful when there is a treatment to act on it.
A positive blood test generally leads to scans or other checks to locate any cancer, rather than starting treatment directly. The test shows that cancer DNA is present but not where it is or how much there is. Doctors may then discuss whether earlier treatment helps in your situation, which is still being studied for many cancers.
What Happens to Your Results Later
Rereading results requires that the lab keep the original data.26PubMed Central. Is There a Duty to Reinterpret Genetic Data? The Ethical Dimensions For gene panels, the list of changes is usually enough to reinterpret later.26PubMed Central. Is There a Duty to Reinterpret Genetic Data? The Ethical Dimensions Who must reinterpret uncertain findings, and when, is still unsettled.27PubMed Central. Ethical, legal, and social implications of incorporating genomic information into electronic health records So ask your doctor or lab whether they will contact you if a result is reclassified.
Knowledge about which gene changes matter keeps growing, so a change labeled uncertain today may be classified as harmful or harmless later. New drugs may also be approved for a change that had no matching treatment when you were first tested. A result from years ago may be worth another look if your cancer returns or stops responding.
Request the full report, not just a summary, and keep your own copy. Bring it to new doctors or trial screenings.

